Abstract
There is a growing need for new agents to combat resistant bacteria. This talk will describe the discovery and optimization of a series of adenosine inhibitors targeting bacterial NAD+-dependent DNA ligase (LigA). These compounds exhibit antibacterial activity against a range of Gram positive pathogens, including S. pneumoniae and S. aureus. In vivo efficacy was demonstrated for the first time for LigA, thus validating its potential use as a target for antibacterial therapy.